Investigate the Effect of Ezetimibe, Simvastatin, and Omega 3- Fatty Acids on Dyslipidemia Patients: a Pharmacokinetics Based Study

• Conditions: Hyperlipidemia; Mixed
• Interventions: Drug: Ezetimibe 10mg

• Registration Number: NCT05080140
• Lead Sponsor: Misr University for Science and Technology

Brief Summary

This randomized controlled pharmacokinetic based study will be carried out on patients with both sexes and various ages, plasma triglycerides levels, clinical health disorders and using different agents for treatment of their hyperlipidemia in order to access the optimal drug therapy with best cost effectiveness in the elderly cases under investigation.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-06-01
• Primary Completion: 2021-07-01
• Status Verified: 2021-10
• Study First Submitted: 2021-10-02
• Study First Submitted QC: 2021-10-02
• Last Update Submitted: 2021-10-02
• Study First Posted: 2021-10-15
• Last Update Posted: 2021-10-15
• Study Completion: 2022-03-20

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 3

Inclusion Criteria

• Patients of dyslipidemia with high triglyceride level (200 to 499 mg/100 ml).
• Total cholesterol level more than 200 mg/100 ml
• Male and female
• Age 35 - 70 years

Exclusion Criteria

• • Hypersensitivity of drugs
• Liver toxicity
• -Patients suffering from renal dysfunction

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Simvastain + ezetimibe + omega	Ezetimibe 10mg	-
Ezetimibe	Ezetimibe 10mg	-
Simvastatin+ Ezetimibe	Ezetimibe 10mg	-

Primary Outcome Measures

Name	Time	Method
Reduction of Total cholesterol	3 months	reduction of LDL

Trial Locations

Locations (1)

Misr University for science and technology; 🇪🇬 Giza, Egypt